MOTS-c: The Mitochondrial-Derived Peptide in Metabolic Research

What Is MOTS-c?

MOTS-c was identified and characterized in 2015 by a research group led by Dr. Changhan David Lee at the University of Southern California. At the time of its discovery, it was recognized as the first peptide known to be both mitochondrially-encoded and capable of translocating from mitochondria to the cell nucleus to regulate gene expression — a previously uncharacterized type of intercellular signaling.

MOTS-c belongs to a class of small peptides called mitochondrial-derived peptides (MDPs), which includes humanin and the SHLP family (Small Humanin-Like Peptides). These are encoded in short open reading frames within mitochondrial rRNA sequences that were previously classified as non-coding. MOTS-c is the most studied of the metabolically active MDPs.

Discovery and Research Context

When MOTS-c was first published in Cell Metabolism in 2015, the finding challenged established assumptions about the mitochondrial genome. The canonical view held that mitochondrial DNA encodes only the 13 subunits of the oxidative phosphorylation machinery, 22 tRNAs, and 2 rRNAs — not regulatory peptides.

The identification of MOTS-c as a bioactive peptide arising from within mitochondrial rRNA sequences opened a new field of inquiry: how much of the mitochondrial genome encodes functional regulatory molecules that have been overlooked due to their small size? Current research suggests the MDP family may be considerably larger than initially recognized.

Mechanism of Action

MOTS-c acts through several interconnected metabolic pathways:

AMPK activation

The central mechanism of MOTS-c is the activation of AMP-activated protein kinase (AMPK), the master regulator of cellular energy sensing. AMPK becomes active when cellular AMP:ATP ratios rise — a signal of energy stress. Its activation triggers a shift toward oxidative metabolism and suppresses anabolic processes.

MOTS-c activates AMPK through modulation of the folate cycle — specifically by inhibiting the AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) transformylase enzyme ATIC within the purine biosynthesis pathway. This results in intracellular AICAR accumulation, which is a known AMPK activator. The pathway is distinct from direct AMPK binding and represents a novel route for endogenous AMPK activation.

Glucose metabolism and fatty acid oxidation

AMPK activation downstream of MOTS-c promotes:

• Glucose uptake through GLUT4 translocation in muscle cell models
• Inhibition of de novo fatty acid synthesis (FASN suppression)
• Promotion of fatty acid oxidation in liver and muscle cell models
• Regulation of folate metabolism and one-carbon metabolism

Nuclear translocation under stress

Under cellular stress conditions (heat shock, oxidative stress, nutrient restriction), MOTS-c has been observed to translocate from the mitochondria to the nucleus. In the nucleus, it binds to the ARE (antioxidant response element) and influences the expression of genes involved in stress response, redox balance, and metabolic adaptation. This nucleus-targeting behavior makes MOTS-c unusual among mitochondrial peptides.

Systemic circulation

Published research has demonstrated that MOTS-c is detectable in human plasma, with levels varying by age and metabolic status. Older individuals and those with metabolic dysfunction show lower circulating MOTS-c levels in cross-sectional studies, suggesting a potential role as a biomarker of mitochondrial health.

Research Applications

MOTS-c has been studied in the following preclinical contexts:

In mouse models, exogenous MOTS-c administration has been associated with improved glucose tolerance, increased insulin sensitivity, and resistance to high-fat-diet-induced metabolic dysregulation. Effects appear to be mediated through skeletal muscle AMPK activation.

Multiple published studies suggest MOTS-c mimics some effects of physical exercise in animal models — particularly in terms of glucose uptake and mitochondrial function. Research by the Lee group demonstrated that exogenous MOTS-c enhanced exercise capacity and endurance in aged mice, a finding that has attracted interest in the context of age-related decline research.

MOTS-c has been investigated in Caenorhabditis elegans longevity models, where exogenous administration extended lifespan in a manner dependent on DAF-16 (the C. elegans homolog of FOXO transcription factors). Mammalian longevity implications remain a subject of ongoing research. For researchers studying peptidergic longevity compounds through different mechanisms, Epitalon represents a complementary approach via telomerase activation and pineal regulation. Researchers exploring the SIRT1/SIRT3 axis as a complementary longevity pathway may also see NAD+, whose availability directly gates sirtuin activity downstream of the same metabolic sensing network MOTS-c feeds into via AMPK.

Cell culture studies have examined MOTS-c's role in protecting against oxidative stress, with reported effects on reactive oxygen species (ROS) levels and mitochondrial membrane potential.

Emerging research suggests MOTS-c may modulate inflammatory signaling, with reported effects on NF-κB pathway activity in macrophage cell culture models.

Dose Forms and Handling

MOTS-c is supplied as a lyophilized powder. Because of its short sequence (16 amino acids) and lack of disulfide bonds or other complex structural features, it reconstitutes readily in bacteriostatic water at standard research concentrations.

• Storage (lyophilized): −20 °C in sealed, dry conditions. Stable for 12–24 months.
• Storage (reconstituted): 2–8 °C for short-term use; aliquot and freeze at −20 °C for longer storage.

Refer to our reconstitution protocol and storage guide for handling best practices.

Research Notes

Several aspects of MOTS-c research are worth noting when designing experiments:

• Sequence conservation: MOTS-c sequence shows high conservation across primates and moderate conservation in rodents. Cross-species studies should account for sequence differences.
• Exogenous vs. endogenous: Published studies typically use exogenous peptide administration (subcutaneous or intraperitoneal injection in animal models). The relationship between exogenous MOTS-c levels and endogenous signaling pathways requires careful interpretation.
• AMPK dependency: Several MOTS-c effects appear to be AMPK-dependent; researchers using AMPK knockout or pharmacological AMPK inhibitors should expect attenuated or absent MOTS-c effects in those contexts.

Product Availability

Phase 1 Peptides stocks MOTS-c at 99%+ purity with third-party laboratory documentation:

• MOTS-c — research-grade, multiple dose sizes

Summary

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA — one of the first characterized mitochondrial-derived peptides with clear metabolic regulatory activity. Its primary mechanism involves AMPK activation through folate cycle modulation, with downstream effects on glucose metabolism, fatty acid oxidation, and cellular stress response. It is notable for nuclear translocation under stress conditions and for displaying exercise-mimetic properties in animal models. As a relatively newly characterized mitochondrial signaling molecule, MOTS-c represents an active and open research frontier in mitochondrial biology and metabolic research.

Researchers building a broader mitochondrial research framework may also see SS-31 (Elamipretide), which targets the inner mitochondrial membrane at the structural level via cardiolipin binding rather than through AMPK-mediated gene expression — a complementary mitochondrial research angle. For a side-by-side overview of all four major mitochondria-focused research compounds (MOTS-c, SS-31, NAD+, glutathione), see the Mitochondrial Research Compounds overview.

MOTS-c is encoded entirely within mitochondrial DNA — specifically within the 12S ribosomal RNA gene — making it one of the first characterized peptides with a purely mitochondrial genetic origin. More unusually, MOTS-c can translocate from mitochondria to the cell nucleus under stress conditions, where it modulates gene expression at antioxidant response elements. This nuclear-targeting behavior distinguishes it from typical mitochondrial proteins.

MOTS-c activates AMP-activated protein kinase (AMPK) indirectly through the folate cycle. It inhibits the ATIC enzyme within the purine biosynthesis pathway, causing intracellular accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). AICAR is a known endogenous AMPK activator. This route to AMPK activation is mechanistically distinct from direct AMPK binding and represents a novel pathway for endogenous energy-sensing regulation.

Several published animal studies report that exogenous MOTS-c administration produces metabolic effects in rodent models that resemble those of physical exercise — including improved glucose uptake, increased mitochondrial function, and enhanced endurance capacity. This characterization is based on the overlap between MOTS-c's downstream AMPK-driven effects and the metabolic adaptations associated with exercise, not on MOTS-c replicating exercise mechanically.

Cross-sectional studies report that circulating MOTS-c levels in plasma are lower in older individuals and in those with metabolic dysfunction compared to younger or metabolically healthy subjects. This age-dependent decline in endogenous MOTS-c is one basis for its investigation as a potential biomarker of mitochondrial health and for research into whether exogenous administration can compensate for age-related declines.

All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.